Prothena Corporation plc (Nasdaq: PRTA) is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by a deep scienti...
Prothena Corporation plc (Nasdaq: PRTA) is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by a deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena's pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. Prior to December 2012, Prothena's business operated as part of Elan Corporation, plc. Prothena's business consists of a substantial portion of Elan's former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan's stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol "PRTA" on December 21, 2012. For more information, please visit our website at www.prothena.com